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Abstract The aim of this study was to evaluate the
effectiveness of an additional, individualized, multi-com-
ponent complementary medicine treatment offered to breast
cancer patients at the Merano Hospital (South Tyrol) on
health-related quality of life compared to patients receiving
usual care only. A randomized pragmatic trial with two
parallel arms was performed. Women with confirmed diag-
noses of breast cancer were randomized (stratified by usual
care treatment) to receive individualized complementary
medicine (CM group) or usual care alone (usual care group).
Both groups were allowed to use conventional treatment for
breast cancer. Primary endpoint was the breast cancer-rela-
ted quality of life FACT-B score at 6 months. For statistical
analysis, we used analysis of covariance (with factors
treatment, stratum, and baseline FACT-B score) and imputed
missing FACT-B scores at 6 months with regression-based
multiple imputation.A total of 275 patientswere randomized
between April 2011 and March 2012 to the CM group
(n = 136, 56.3 ± 10.9 years of age) or the usual care group
(n = 139, 56.0 ± 11.0). After 6 months from randomiza-
tion, adjusted means for health-related quality of life were
higher in the CM group (FACT-B score 107.9; 95 % CI
104.1–111.7) compared to the usual care group (102.2;
98.5–105.9) with an adjusted FACT-B score difference
between groups of 5.7 (2.6–8.7, p\ 0.001). Thus, an addi-
tional individualized and complex complementary medicine
intervention improved quality of life of breast cancer patients
compared to usual care alone. Further studies evaluating
specific effects of treatment components should follow to
optimize the treatment of breast cancer patients.
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Introduction
The demand for complementary medicine (CM) in cancer
patients is growing [1]. In Europe, 30–40 % of cancer
patients use some form of CM [1, 2]. Women with breast
cancer are the largest group [2–4] with an increasing demand
[5]. The main reasons for usage are improvement of quality
of life, physical andmental well-being, boosting the immune
system, and alleviating side effects of the conventional
treatments [2, 4, 6–8]. Dietary supplements, herbal medi-
cines, and mind–body techniques are the most frequently
used modalities [2–4, 7, 9]. There is a need to evaluate CM
especially in breast cancer patients, preferably within ran-
domized trials [10]. However, previous studies have mainly
focused on single interventions, although most patients use
more than one CM modality [11, 12].
In most medical fields, evidence that directly informs
clinical and health policy decision making is needed [13].
Published evidence from clinical trials in oncology often
differs from observations made in a usual care patient pop-
ulation [14]. Comparative Effectiveness Research (CER)
emphasizes the comparison of different treatment options in
usual care settings by including more heterogeneous
patients, using less standardized treatment protocols and
measuring patient-centered outcomes [15]. The Institute of
Medicine in theUSmentioned cancer as one priority forCER
[16]. A broad spectrum of methods can be applied to CER
including randomized trials [17–19]. These so-called
‘‘pragmatic trials’’ play an important role in CER [20] with
the advantage that they maintain internal validity deriving
from randomization while being designed and implemented
to increase external validity. This enables a better assessment
of real-world benefits and risks, and the results can guide
clinical and health policy decisions [20]. Pragmatic trials do
not necessarily have to be blinded or double blinded [10].
In January 2010, the regional public health system in
South Tyrol (Italy) established a service for CM at the
Merano Hospital planned to run for 2 years, and aiming to
improve quality of life in cancer patients and patients with
chronic conditions. The present study was initiated by the
regional public health system to inform the decision whe-
ther or not the service should be maintained after Decem-
ber 2012. Therefore, the primary aim of this study was to
evaluate the effectiveness of an additional, individualized,
multi-component CM treatment offered at the Merano
Hospital compared to usual care only on health-related
quality of life in patients with breast cancer.
Materials and methods
Design
Following the recommendations for CER, we conducted a
pragmatic randomized trial [19, 20]. Patients were allo-
cated to a group that received a complex individualized
CM treatment from the service for CM at the Merano
Hospital, Italy, in addition to usual care (CM group) or to a
group that received no additional CM treatment (usual care
group). The study period per patient was 6 months. The
duration of the treatment varied between patients due to the
highly individualized treatment, but was terminated after a
maximum of 6 months. The patients of the usual care
group received no CM treatment at the Merano Hospital
during the first 6 months, but to reduce patient selection
bias they were offered the respective treatment after the
end of the study. The CM therapy within the study was free
of charge. Usual care was conducted following oncologic
guidelines and after interdisciplinary tumor boards and was
covered by the patients’ health insurance. The study pro-
tocol was approved by the local ethics committee of South
Tyrol (statement 10/2011).
Patients
Patients with a diagnosis of breast cancer were recruited
between April 2011 and March 2012 in breast cancer
centers of Merano, Bressanone, and Bolzano, Italy. After
meeting the inclusion criteria and providing written
informed consent, they were randomized in a 1:1 ratio and
stratified according to the planned usual care treatment
during the study period (four strata: chemotherapy, endo-
crine therapy, chemotherapy and endocrine therapy, neither
chemotherapy nor endocrine therapy). The randomization
list was generated using the software SAS (SAS Inc., Cary
NC, USA) by a statistician not further involved in the study
and was embedded in a secure database. None of the study
personnel had access to the randomization list before the
actual allocation. Screening, randomization, and enrolling
of the study participants was done at the onsite study
office by a psychologist not involved in the intervention.
After registration of the patient details in the database,
randomization was performed using a randomization
control.
Patients were included if they had a verified diagnosis of
breast cancer, were receiving usual care for cancer or
related symptoms at the time of the study, and were willing
to refrain from CM treatment for 6 months if they were
randomized to the usual care group. Exclusion criteria were
a CM treatment at the Merano Hospital during the period of
6 months prior to the study, insufficient language ability,
and participation in another study.
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Interventions
All patients received their usual oncological care from those
breast cancer centers theywere routinely seeing as part of their
cancer treatment. The treatment components, the frequency,
and the overall duration of the additional complex and indi-
vidualized CM treatment of the CM group were highly indi-
vidualized according to the patient’s clinical presentation and
her needs and taking into account possible interaction with
conventional treatment. Components of the treatments
included infusions according to the patient’s hemogram and
conventional treatment (with ingredients such as alpha factor,
high-dosage vitamin C, selenium, carnitine, vitamins), acu-
puncture (e.g., for treating pain and nausea), hyperthermia,
movement therapy (e.g., qigong), enzyme therapy, laser
therapy (especially for patients with oral mucositis), mistletoe
therapy, orthomolecular therapy, osteopathy, phytotherapy
incl. Chinese herbal medicine. Physicians, nurses, and phys-
iotherapists of the CM service conducted the treatments.
Outcome measures
At baseline, patients’ socio-demographic as well as cancer-
related data were documented. Where available, data were
obtained from the hospitals’ clinical health records.
The primary outcome parameter was disease-related
quality of life assessed with the Functional Assessment of
Cancer Therapy-Breast (FACT-B) [21] after 6 months.
Secondary outcome parameters were the FACT-B after
3 months, after 3 and 6 months the FACT-General (G) [22]
subscales (physical, functional, social, and emotional well-
being), the FACT-B subscale Breast, three single items of
the FACT-G (pain, sleep, and nausea), fatigue assessed
with the FACIT-fatigue scale [23], health-related quality of
life assessed with the SF-12 [24], and after 6 months the
proportion of responders, relapse-free survival, overall
survival, adverse events (AEs), and treatment interactions.
AEs were extracted from clinical health records. In the CM
group, AEs and possible interactions between therapies
were also documented by the CM doctor as well as changes
of the CM or conventional treatment due to adverse events.
Patients in the CM group were asked to rate the overall
effectiveness and their satisfaction with the CM intervention
after 3 and 6 months. Furthermore, at baseline, patients in the
CM group decided together with their physicians on up to
three treatment goals that were evaluated after 3 months
independently by patient and physician and after 6 months
by the patient only (goal attainment scaling).
Patients completed paper–pencil questionnaires at
baseline, after 3 and after 6 months. The questionnaires
were available in German and Italian, the official languages
in South Tyrol. The patients completed the questionnaires
at home and mailed them back to the study office that was
responsible for all data collection. They were reminded by
telephone if they failed to send back a questionnaire.
Statistics
Sample size calculation
Assuming an effect size of 0.35 (small to moderate effect)
regarding the FACT-B at 6 months, a power of 80 %, and a
two-sided t test with an alpha of 0.05, 130 patients have to
be included in each group. Allowing for dropouts, 280
patients were to be included in the study.
Analyses
Data analyses followed a predefined and signed statistical
analysis plan (SAP) agreed upon by the Steering Committee.
Socio-demographic and disease-related characteristics at
baseline are presented as means with standard deviation for
continuous data and frequencies with percentages for cate-
gorical data. The primary analysis of the primary endpoint
(FACT-B score after 6 months) was performed by analysis of
covariance (ANCOVA) including the treatment and stratum
variables as fixed effects, and the baseline FACT-B score as
covariate. Results for the treatment effect are presented as
adjusted means for each treatment group and for the group
difference, with 95 % confidence intervals and the corre-
sponding p value. The p value was two-sided and the type I
error level was set at 0.05. This analysis was performed on the
intention-to-treat (ITT) population with multiple imputation
of missing FACT-B scores after 6 months. Multiple imputa-
tion was performed using SAS PROC MI and PROC MI-
ANALYZE (SAS for Windows Version 9.3, SAS Institute
Inc., Cary, NC USA) with a Markov Chain Monte Carlo
(MCMC)method stratified by treatment group. Five thousand
iterations were used before the first imputation and 5,000
iterations were performed between successive imputations.
The number of imputations was set to 100. The selection of
imputation variables and the primary analyses of the primary
endpoint were performed blinded to treatment allocation. All
further analyses (secondary outcomes, further time points,
subgroups, and sensitivity analyses) were performed without
missing imputations and were considered exploratory.
Sensitivity analyses for the primary endpoint included the
same ANCOVAmodel without imputation of missing value
and using the last observed FACT-B value for imputation
(LOCF). In addition, the primary analysis model was
extended to adjust for further characteristics at baseline
(education, income, previous CM use, attitude toward CM).
Secondary endpoints were analyzed using ANCOVA by
adjusting for baseline values (where available) and randomi-
zation stratum for continuous variables. For binary endpoint
outcomes (e.g., proportion of responders, defined by a FACT-
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B score improved by C7 points), logistic regression adjusted
for baselinevalues and randomization stratumwas used.Effect
size for the primary endpoint (adjusted for baseline value and
stratum) was calculated post hoc (not described in the SAP).
Adverse events will be presented descriptively presenting
number and percentage of patients with adverse events
(compared between treatment groups by Chi-square test).
Predefined subgroup analyses were planned using
models as described above with interaction terms between
treatment group and subgroup regarding the following
baseline characteristics: randomization stratum, time since
first diagnosis of breast cancer, time since last recurrence,
cancer stage, tumor grade, number of recurrences, age
groups, and native language (German, Italian).
For the safety analysis, AEs were classified according
to the Common Terminology Criteria for Adverse Events
established by the US National Cancer Institute [25]. An
independent samples t test was conducted to compare the
mean number of AEs documented in the patient’s record
between the two groups. The frequency distributions of the
different AE categories in the two groups were compared
via Chi-square test. The mean number of AEs that was
only documented by the CM doctor, and the frequency of
different AE categories of these AEs also was computed.
Results
Between April 2011 and March 2012, a total of 442
patients were screened for eligibility to participate in the
study (Fig. 1). A total of 275 patients were randomized,
136 to the CM group, 139 to the usual care group. Data for
the main effectiveness analysis were available for 234
patients (85 %, Fig. 1). Baseline characteristics and med-
ical history were mostly comparable between both study
groups (Table 1). The overall attitude toward CM was very
136 Allocated to Complementary Medicine 139 Allocated to no intervention (usual care)
118 Followed up at 3 months 
15 refused further participation in the 
study                                                         
1 lost to follow up
2 without giving reasons
118 Follow-up at 3 months
14 refused further participation in the study
5 lost to follow up
2 patients died
114 Followed up at 6 months




1 without giving reasons
113 Follow-up at 6 months
1 refused further participation in the study
2 patients died
1 later exclusion because of wrong 
diagnosis
1 without giving  reasons
117 used for primary endpoint analysis   
based on ITT  
19 no FACT-B at baseline
117 used for primary endpoint analysis 
based on ITT 
22 no FACT-B at baseline
442 Patients contacted
164 Patients Center Meran
157 Patients Center Brixen
121 Patients Center Bozen
33 excluded Center Meran
93 excluded Center Brixen
41 excluded Center Bozen
5 did not meet inclusion criteria: 
2 Center Meran
1 Center Brixen         
2 Center Bozen







































ITT = Intention to treat
Fig. 1 CONSORT flow chart for the study
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Table 1 Baseline characteristics and medical history
Complementary medicine
group (n = 136)
Mean ± SD/n (%)
Usual care
group (n = 139)
Mean ± SD/n (%)
Age (years) 56.3 ± 10.9 56.0 ± 11.0
School education
[10 years of schooling 78 (60.5 %) 76 (58.5 %)
Primary language
German 96 (70.6 %) 97 (69.8 %)
Italian 40 (29.4 %) 42 (30.2 %)
Family income (€/months)
\2000 Euro 71 (71.7 %) 51 (55.4 %)
C2000 Euro 28 (28.3 %) 41 (44.6 %)
Breast cancer center
Bozen 35 (25.7 %) 46 (33.1 %)
Brixen 33 (24.3 %) 32 (23.0 %)
Meran 68 (50.0 %) 61 (43.9 %)
Years since first diagnosis 3.4 (3.2) 3.1 (3.2)
Tumor type
Carcinoma in situ 32 (23.9 %) 34 (25.2 %)
Invasive ductal carcinoma 104 (77.6 %) 104 (77.0 %)
Invasive lobular carcinoma 19 (14.2 %) 24 (17.8 %)
Inflammatory breast cancer 0 (0 %) 0 (0 %)
Tumor stage (first diagnosis or last relapse)
Stage 0 7 (5.4 %) 5 (3.8 %)
Stage I 57 (43.8 %) 51 (38.6 %)
Stage II 47 (36.2 %) 59 (44.7 %)
Stage III 16 (12.3 %) 9 (6.8 %)
Stage IV 3 (2.3 %) 8 (6.1 %)
Tumor grading
G1 13 (10.1 %) 17 (13.4 %)
G2 58 (45.0 %) 56 (44.1 %)
G3 58 (45.0 %) 54 (42.5 %)
Relaps
None 126 (92.6 %) 133 (95.7 %)
1 8 (5.9 %) 6 (4.3 %)
C2 2 (1.5 %) 0 (0 %)
Menopause
Pre-/perimenopausal 51 (39.8 %) 60 (46.9 %)
Postmenopausal 77 (60.2 %) 68 (53.1 %)
Previous surgery
Breast conserving (lumpectomy or Quadrantectomy) 112 (78.0 %) 104 (79.4 %)
Mastectomy 34 (25.8 %) 34 (26.0 %)
Undefined surgery 2 (1.5 %) 3 (2.3 %)
Previous radiation therapy
External radiation 83 (66.9 %) 87 (73.1 %)
Brachytherapy 1 (0.8 %) 1 (0.8 %)
Undefined radiation 6 (4.8 %) 4 (3.4 %)
Previous chemotherapy 62 (50.8 %) 64 (53.3 %)
Previous hormone therapy
Tamoxifen or fulvestarant 13 (11.2 %) 8 (7.0 %)
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positive, although only 23 % of the patients in the CM
group and 34 % of patients in the usual care group had
used CM before (Table 1).
During the study, patients in the CM group were indi-
vidually treated (Table 2). The conventional oncological
treatment was comparable in both groups and patients of
both groups used CM outside the service of the Merano
Hospital (Table 3).
In the primary analysis after 6 months, adjusted means
for health-related quality of life were higher in the CM
group (FACT-B score 107.9; 95 % CI 104.1–111.7) com-
pared to the usual care group (102.2; 98.5–105.9) with an
Table 1 continued
Complementary medicine
group (n = 136)
Mean ± SD/n (%)
Usual care
group (n = 139)
Mean ± SD/n (%)
AIs 8 (6.9 %) 7 (6.1 %)
LHRH analog 7 (6.0 %) 2 (1.7 %)
Previous antibody therapy 10 (8.5 %) 6 (5.6 %)
Previous bisphosphonate therapy 6 (5.2 %) 11 (10.1 %)
Stratification group
Chemotherapy 15 (11.0 %) 15 (10.8 %)
Hormones 80 (58.8 %) 79 (56.8 %)
Chemotherapy ? hormones 1 (0.7 %) 3 (2.2 %)
No chemotherapy ? no hormones 40 (29.4 %) 42 (30.2 %)
Previous use of complementary medicine (most frequent)
Any 30 (22.9 %) 45 (34.4 %)
Acupuncture 11 (8.4 %) 11 (8.6 %)
Bach flowers 6 (4.6 %) 7 (5.5 %)
Homeopathy 12 (9.2 %) 15 (11.7 %)
Meditation 2 (1.5 %) 6 (4.7 %)
Mistletoe 5 (3.8 %) 8 (6.3 %)
Other phytomedicine 6 (4.6 %) 4 (3.1 %)
Qigong/Tai Chi/Yoga 3 (2.7 %) 9 (7.0 %)
Other 17 (13.0 %) 30 (23.4 %)
Attitudes toward complementary medicine
I do not believe that it works 3 (2.3 %) 0 (0 %)
Only in addition to conventional medicine 67 (52.3 %) 73 (57.0 %)
Could be a good alternative to conventional medicine 57 (44.5 %) 49 (38.3 %)
Overall more effective than conventional medicine 1 (0.8 %) 6 (4.7 %)
FACT-B 98.3 ± 19.2 100.7 ± 19.5
FACT-G subscales
Physical well-being 20.9 ± 5.7 21.5 ± 5.3
Social and family well-being 19.3 ± 5.7 19.5 ± 5.8
Emotional well-being 18.1 ± 4.0 17.8 ± 4.1
Functional well-being 17.1 ± 5.7 18.2 ± 5.1
FACT-G single items
Pain 1.3 ± 1.2 1.2 ± 1.2
Sleep 1.9 ± 1.2 2.1 ± 1.3
Nausea 0.5 ± 0.9 0.4 ± 0.8
FACIT-fatigue scale 36.3 ± 11.0 36.5 ± 11.2
Quality of life (SF-12)
Mental component scale 44.0 ± 10.2 44.8 ± 11.8
Physical component scale 43.9 ± 9.7 44.0 ± 10.4
SD Standard deviation, FACT-B Functional Assessment of Cancer Therapy-Breast, FACT-G Functional Assessment of Cancer Therapy General,
FACIT Functional Assessment of Chronic Illness Therapy
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adjusted FACT-B score difference between groups of 5.7
(2.6–8.7, p\ 0.001).
This improvement was robust in the sensitivity analyses
for missing data and the extended model adjusting for
further characteristics at baseline (data not shown).
Responder rates were higher in the CM group compared to
the usual care group (adjusted odds ratio 0.4, 95 % CI
0.2–0.7, p = 0.003). The adjusted effect size for the dif-
ference between groups according to Cohen’s d was 0.53.
No subgroup showed a significant effect modifying influ-
ence regarding FACT-B at 6 months.
For most secondary outcomes, the results of the patients
in the CM group were superior to those in the usual care
group (Table 4). Three patients died during the study (1 in
the CM group and 2 in the usual care group, Fig. 1), and
one relapse occurred in the usual care group. Before the
intervention, patients in the CM group defined with their
physicians on average 2.6 ± 0.7 treatment goals and
assessed those after 3 and 6 months. (Table 5). The patients
were mostly satisfied with the CM treatment and found it
effective (Table 5).
Safety
The mean number of AEs documented in the patient’s
records was 0.52 (SD = 1.14) in the CM group and 0.64
(2.10) in the usual care group (p = 0.56). Most AEs
belonged to the spectrum of musculoskeletal and connec-
tive tissue disorders (22.5 %), gastrointestinal disorders
(13.1 %), and general disorders (13.1 %), with no signifi-
cant difference between groups (p = 0.41, Table 6). The
additional documentation for the CM patients resulted in a
mean number of 2.92 (SD = 1.63) AEs per patient. Most
of these AEs were musculoskeletal and connective tissue
disorders (24.4 %), followed by psychiatric disorders
(20.4 %), and general disorders (16.1 %) (Table 6). For
two patients in the CM group, the CM treatment was
changed due to AEs, and for two patients in the usual care
group, the conventional treatment was changed due to AEs.
Discussion
Breast cancer patients treated with an individualized multi-
component CM treatment at the Merano Hospital showed
significant improvements in disease-specific quality of life
and fatigue compared with patients who received standard
care alone.
To our knowledge, the present study is the first ran-
domized trial in breast cancer patients evaluating the
effectiveness of a complex and individualized CM inter-
vention in a usual care setting. We used the framework of
CER and designed a pragmatic trial [19] that allowed us to
answer the question if the CM service implemented by the
regional public health system had a positive effect on
quality of life of cancer patients and should be maintained.
We focused on breast cancer patients because they made
up the largest group using the respective service. Thus the
study results cannot be transferred to other patients. Fur-
thermore, the results relate to the specific interventions and
setting of the Hospital Merano and cannot be transferred to
other interventions and settings.
Advantages of our approach to provide useful informa-
tion for decision making regarding continuation of the
service included an outcome measure that was recom-
mended for incorporating patient-reported outcomes into
CER [26], a setting and intervention that reflected usual
care, broad eligibility criteria, and the participation of all
existing breast cancer centers in the region.
Clearly, this kind of approach also has methodological
limitations. Neither physicians nor patients were blinded to
treatment. To minimize social acceptability bias, all ques-
tionnaires were sent directly from and to the psychologist
who was not further involved in the patients’ treatment.
However, bias regarding the patient-reported main out-
come resulting from non-blinding to the intervention can-
not be ruled out. Also, there might be bias attributable to
participating physicians’ and practitioners’ positive atti-
tudes about CM, their affiliation with the governmental
Table 2 Treatment in the complementary medicine group (study
intervention)
Complementary medicine
Mean ± SD/n (%)
Individualized study intervention
Acupuncture 66 (48.5 %)
Number of treatments 6.9 ± 3.9
Dietary advice 20 (14.7 %)
Healing touch 1 (0.7 %)
Homeopathy 62 (45.6 %)
Hyperthermia 3 (2.2 %)
Infusions 59 (43.4 %)
Number of treatments 9.25 ± 6.55
Laser therapy 17 (12.5 %)
Number of treatments 4.00 ± 2.31
Lymphatic drainage 4 (2.9 %)
Magnet field therapy 19 (14.0 %)
Number of treatments 7.6 ± 6.1
Manual therapy 2 (1.5 %)
Neural therapy 8 (5.9 %)
Orthomolecular therapy 66 (48.5 %)
Osteopathy 26 (19.1 %)
Number of treatments 5.7 ± 2.7
Phytotherapy 35 (25.7 %)
Shiatsu 1 (0.7 %)
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project, and possible personal or financial interests in
producing results in favor of CM. Our inclusion criteria
were broad, which resulted in a heterogeneous patient
sample and diagnostic misclassification can happen in this
type of study. We had one patient claiming to have breast
cancer, who was randomized to the usual care group. When
comparing her interview data with the clinical health
records, the diagnosis could not be confirmed. Using a
more conservative approach by strictly following ITT
analyses, we included her in the primary analysis, but
performed an additional sensitivity analysis without this
patient, which did not change the results. That not all
patients received the treatment that was planned at baseline
cannot be avoided in a study that reflects usual care.
Finally, our patients had a highly positive attitude
toward CM treatment. However, adjusting for attitude in a
sensitivity analysis did not change the main outcome.
Although the issues mentioned above are considered lim-
itations from an experimental perspective, the study design
was chosen to reflect general medical practice as closely as
possible. A more experimental approach would not have
been suitable to answer the study question.
It is important to highlight that this study does not
provide any information on the effectiveness of the single
CM modalities used within the complex intervention.
Further studies separating different modalities, perhaps
multi-armed studies would be needed to generate evidence
on this question. In fact, there are studies on single com-
plementary treatment modalities for breast cancer patients,
e.g., on acupuncture used for the alleviation of symptoms
caused by aromatase inhibitors [27–29], or for treating
cancer-related fatigue [30, 31].
Furthermore, this study cannot answer the question of
how much of the observed effects can be attributed to non-
specific effects. Based on evidence that some of the
interventions have relevant non-specific effects (i.e. acu-
puncture) [32], those also contribute to our results. The
numbers of AEs were low and did not differ in both groups.
Table 3 Concomitant
treatments in both groups
Complementary
medicine n (%)
Usual care n (%)
3 months 6 months 3 months 6 months
Complementary medicine outside the study
Any 11 (9.6 %) 19 (16.8 %) 27 (23.7 %) 25 (22.5 %)
Acupuncture 4 (3.5 %) 4 (3.5 %) 5 (4.5 %) 2 (1.8 %)
Bach flowers 1 (0.9 %) 1 (0.9 %) 2 (1.8 %) 2 (1.8 %)
Homeopathy 8 (7.0 %) 7 (6.2 %) 10 (8.9 %) 6 (5.5 %)
Meditation 1 (0.9 %) 4 (3.5 %) 4 (3.6 %) 5 (4.6 %)
Mistletoe 3 (2.6 %) 4 (3.5 %) 3 (2.7 %) 5 (4.6 %)
Other phytomedicine 1 (0.9 %) 2 (1.8 %) 4 (3.6 %) 2 (1.8 %)
Qigong/Tai Chi/Yoga 2 (1.8 %) 5 (4.4 %) 5 (4.5 %) 7 (6.4 %)
Other 9 (7.8 %) 14 (12.6 %) 19 (16.9 %) 17 (15.6 %)




0 (0 %) 0 (0 %)
Mastectomy 1 (0.8 %) 1 (0.8 %)
Undefined surgery 1 (0.8 %) 1 (0.8 %)
Radiation therapy
External 10 (8.1 %) 7 (5.9 %)
Brachytherapie 0 (0 %) 0 (0 %)
Undefined 1 (0.8 %) 2 (1.7 %)
Chemotherapy 8 (6.6 %) 10 (8.3 %)
Hormone therapy
Tamoxifen o. fulvestarant 27 (23.5 %) 25 (21.7 %)
AIs 51 (44.3 %) 51 (44.3 %)
LHRH analog 18 (15.7 %) 17 (14.8 %)
Antibody therapy 6 (5.1 %) 7 (6.5 %)
Bisphosphonates 3 (2.6 %) 1 (0.9 %)
Patients in hospital (patient reported) 10 (9.0 %) 9 (8.5 %)
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Table 5 Complementary medicine group: patients overall rating of
effectiveness, satisfaction, and goal attainment scaling at 3 and
6 months
Variable 3 months 6 months
Patient Physician Patient
Goal attainment scalinga (mean ± SD)
Goal 1 0.4 ± 1.0 0.4 ± 0.8 0.3 ± 1.0
Goal 2 0.3 ± 1.0 0.2 ± 0.8 0.4 ± 1.0
Goal 3 0.1 ± 1.0 0.1 ± 0.8 0.2 ± 1.0
Average of goal-1-3 0.3 ± 1.0 0.3 ± 0.8 0.3 ± 1.0
Rating of effectiveness
Very effective 18 (15.3 %) 23 (20.2 %)
Effective 88 (74.6 %) 83 (72.8 %)
Small effect 12 (10.2 %) 7 (6.1 %)
No effect 0 (0 %) 1 (0.9 %)
Satisfaction with CM treatment
Very satisfied 50 (42.7 %) 38 (33.3 %)
Satisfied 58 (49.6 %) 68 (59.6 %)
Not very satisfied 9 (7.7 %) 7 (6.1 %)
Not satisfied 0 (0 %) 1 (0.9 %)
a
-2 points worse than expected, -1 no change, 0 aim reached, 1
better than expected, 2 much better than expected








AEs documented in clinical records
Blood and lymphatic
system disorders
1 (1.4 %) 3 (3.4 %) 4 (2.5 %)
Ear and labyrinth
disorders
















Hepatobiliary disorders 1 (1.4 %) 0 (0.0 %) 1 (0.6 %)
Immune system
disorders
1 (1.4 %) 0 (0.0 %) 1 (0.6 %)
Infections and
infestations




2 (2.8 %) 0 (0.0 %) 2 (1.2 %)
Investigations 1 (1.4 %) 2 (2.2 %) 3 (1.9 %)
Metabolisms and
nutrition disorders




















8 (11.3 %) 6 (6.7 %) 14 (8.8 %)





0 (0.0 %) 1 (1.1 %) 1 (0.6 %)
Reproductive system
and breast disorders
2 (2.8 %) 5 (5.6 %) 7 (4.4 %)
Respiratory thoracic and
mediastinal disorders
1 (1.4 %) 0 (0.0 %) 1 (0.6 %)
Skin and subcutaneous
tissue disorders
5 (7.0 %) 6 (6.7 %) 11 (6.9 %)
Vascular disorders 4 (5.6 %) 6 (6.7 %) 10 (6.2 %)











Endocrine disorders 1 (0.3)



































Vascular disorders 34 (8.6)
No code available 6 (1.5)
Total 397 (100)
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In usual care, physicians ask their patients less detailed
questions about AEs than in clinical trials and even if
patients report them, they might not always be documented
[33]. In the CM group, the doctors asked explicitly for AEs,
resulting in additionally documented AEs, especially psy-
chiatric disorders including anxiety, worries, sleeping
problems, or restlessness. This might be explained by the
holistic approach of CM doctors asking for both mind and
body aspects.
It is difficult to compare our study with other studies
because previous studies addressed mainly single CM
modalities, for example, yoga [34] or specific intervention
programs such as mind–body medicine [35, 36]. There are
only few studies that address the topic of complex indi-
vidualized CM interventions in cancer patients in usual
care setting, and none of them used a randomized design
[3, 37, 38].
Conclusion
The additional individualized and complex CM interven-
tion offered by the Hospital Merano was more effective in
improving quality of life compared to no additional CM
intervention in breast cancer patients. Further studies
evaluating the effectiveness, efficacy, and safety of treat-
ment components should follow.
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